C-Myc is a Novel Target of Cell Cycle Arrest by Honokiol in Prostate Cancer Cells

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2016 Jun 25

PMID 27341160

Citations 8

Authors

Eun-Ryeong Hahm

Krishna Beer Singh

Shivendra V Singh

Affiliations

Soon will be listed here.

Abstract

Honokiol (HNK), a highly promising phytochemical derived from Magnolia officinalis plant, exhibits in vitro and in vivo anticancer activity against prostate cancer but the underlying mechanism is not fully clear. This study was undertaken to delineate the role of c-Myc in anticancer effects of HNK. Exposure of prostate cancer cells to plasma achievable doses of HNK resulted in a marked decrease in levels of total and/or phosphorylated c-Myc protein as well as its mRNA expression. We also observed suppression of c-Myc protein in PC-3 xenografts upon oral HNK administration. Stable overexpression of c-Myc in PC-3 and 22Rv1 cells conferred significant protection against HNK-mediated growth inhibition and G0-G1 phase cell cycle arrest. HNK treatment decreased expression of c-Myc downstream targets including Cyclin D1 and Enhancer of Zeste Homolog 2 (EZH2), and these effects were partially restored upon c-Myc overexpression. In addition, PC-3 and DU145 cells with stable knockdown of EZH2 were relatively more sensitive to growth inhibition by HNK compared with control cells. Finally, androgen receptor overexpression abrogated HNK-mediated downregulation of c-Myc and its targets particularly EZH2. The present study indicates that c-Myc, which is often overexpressed in early and late stages of human prostate cancer, is a novel target of prostate cancer growth inhibition by HNK.

Citing Articles

Honokiol inhibits the growth of hormone-resistant breast cancer cells: its promising effect in combination with metformin.

Mikhaevich E, Sorokin D, Scherbakov A Res Pharm Sci. 2023; 18(5):580-591.

PMID: 37842518 PMC: 10568957. DOI: 10.4103/1735-5362.383712.

Leelamine suppresses cMyc expression in prostate cancer cells and inhibits prostate carcinogenesis .

Singh K, Hahm E, Singh S J Cancer Metastasis Treat. 2021; 7.

PMID: 34660908 PMC: 8513473. DOI: 10.20517/2394-4722.2021.08.

The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC.

Wang X, Xing L, Yang R, Chen H, Wang M, Jiang R Mol Cancer. 2021; 20(1):91.

PMID: 34116677 PMC: 8194204. DOI: 10.1186/s12943-021-01383-x.

root extract inhibits fatty acid synthesis in prostate cancer cells.

Kim S, Singh K, Hahm E, Lokeshwar B, Singh S J Tradit Complement Med. 2020; 10(3):188-197.

PMID: 32670813 PMC: 7340880. DOI: 10.1016/j.jtcme.2020.02.002.

RNA-seq reveals novel mechanistic targets of withaferin A in prostate cancer cells.

Kim S, Hahm E, Singh K, Shiva S, Stewart-Ornstein J, Singh S Carcinogenesis. 2020; 41(6):778-789.

PMID: 32002539 PMC: 7351133. DOI: 10.1093/carcin/bgaa009.

References

Arora S, Singh S, Piazza G, Contreras C, Panyam J, Singh A . Honokiol: a novel natural agent for cancer prevention and therapy. Curr Mol Med. 2012; 12(10):1244-52. PMC: 3663139. DOI: 10.2174/156652412803833508. View

Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell P, Govindarajan B . Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem. 2003; 278(37):35501-7. DOI: 10.1074/jbc.M302967200. View

Bretones G, Delgado M, Leon J . Myc and cell cycle control. Biochim Biophys Acta. 2014; 1849(5):506-16. DOI: 10.1016/j.bbagrm.2014.03.013. View

Hirano T, Gotoh M, Oka K . Natural flavonoids and lignans are potent cytostatic agents against human leukemic HL-60 cells. Life Sci. 1994; 55(13):1061-9. DOI: 10.1016/0024-3205(94)00641-5. View

Shigemura K, Arbiser J, Sun S, Zayzafoon M, Johnstone P, Fujisawa M . Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer. 2007; 109(7):1279-89. DOI: 10.1002/cncr.22551. View

Tsai T, Chou C, Cheng F, Chen C . Pharmacokinetics of honokiol after intravenous administration in rats assessed using high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1994; 655(1):41-5. DOI: 10.1016/0378-4347(94)00031-x. View

Koh C, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo A . Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget. 2011; 2(9):669-83. PMC: 3248223. DOI: 10.18632/oncotarget.327. View

Koh C, Bieberich C, Dang C, Nelson W, Yegnasubramanian S, De Marzo A . MYC and Prostate Cancer. Genes Cancer. 2011; 1(6):617-28. PMC: 3092219. DOI: 10.1177/1947601910379132. View

Gao L, Schwartzman J, Gibbs A, Lisac R, Kleinschmidt R, Wilmot B . Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS One. 2013; 8(5):e63563. PMC: 3660401. DOI: 10.1371/journal.pone.0063563. View

10.

Dang C . MYC on the path to cancer. Cell. 2012; 149(1):22-35. PMC: 3345192. DOI: 10.1016/j.cell.2012.03.003. View

11.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

12.

Li W, Wang Q, Su Q, Ma D, An C, Ma L . Honokiol suppresses renal cancer cells' metastasis via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling. Mol Cells. 2014; 37(5):383-8. PMC: 4044309. DOI: 10.14348/molcells.2014.0009. View

13.

Xiao D, Srivastava S, Lew K, Zeng Y, Hershberger P, Johnson C . Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells by causing G2/M arrest and inducing apoptosis. Carcinogenesis. 2003; 24(5):891-7. DOI: 10.1093/carcin/bgg023. View

14.

Sheen J, Dickson R . Overexpression of c-Myc alters G(1)/S arrest following ionizing radiation. Mol Cell Biol. 2002; 22(6):1819-33. PMC: 135614. DOI: 10.1128/MCB.22.6.1819-1833.2002. View

15.

Schorl C, Sedivy J . Loss of protooncogene c-Myc function impedes G1 phase progression both before and after the restriction point. Mol Biol Cell. 2003; 14(3):823-35. PMC: 151562. DOI: 10.1091/mbc.e02-10-0649. View

16.

Hahm E, Karlsson A, Bonner M, Arbiser J, Singh S . Honokiol inhibits androgen receptor activity in prostate cancer cells. Prostate. 2013; 74(4):408-20. PMC: 3946953. DOI: 10.1002/pros.22762. View

17.

Watson P, Ellwood-Yen K, King J, Wongvipat J, LeBeau M, Sawyers C . Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res. 2005; 65(24):11565-71. DOI: 10.1158/0008-5472.CAN-05-3441. View

18.

Chilampalli S, Zhang X, Fahmy H, Kaushik R, Zeman D, Hildreth M . Chemopreventive effects of honokiol on UVB-induced skin cancer development. Anticancer Res. 2010; 30(3):777-83. View

19.

Wen J, Fu A, Chen L, Xie X, Yang G, Chen X . Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model. Int J Cancer. 2009; 124(11):2709-18. DOI: 10.1002/ijc.24244. View

20.

Park E, Min H, Chung H, Hong J, Kang Y, Manh Hung T . Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells. Cancer Lett. 2009; 277(2):133-40. DOI: 10.1016/j.canlet.2008.11.029. View